and safety profile Promising progression free survival median 4.33 months and overall survival median 15.97 months Patients with unmethylated MGMT have a worse response to therapy than methylated MGM.#Early evidence indicates that the combination of 131I-IPA and XRT may have an anti-neoplastic effect...
21qD1a11 s12qDp‘uodsas‘ (0 )`Ipa131awff‘Hapnn‘V (6I)`Ipa1Dpp1paupaauo-od-f1as'O10q-f1as'20-f1as'V (8I)f1asIsuoLSsuosus6wpdV (LT)`I1Dnsoww'Opp pDq'V (9I)nun`Ibu66budr3y`OuDM `usad`V (SI)`Iapasnsp)sdnwduns‘ ( I)’Iaswsnoof 'O ' mo11of 'V(gI )...
Simultaneous quantification of regional myocardial fatty acid metabolism ( 131I-PHIPA 3–10) and perfusion ( 99mTc-MIBI)X-ray microscopycomputerised tomographyinspectionmedical image processing3D inspectionX-ray tomography imagesfabrication-degradation processes...
IPAX-1 was a multicenter, open-label, single-arm phase I study to evaluate carrier-added 4-L-[131I]iodo-phenylalanine ([131I]IPA) plus external radiation therapy (XRT) in recurrent GBM. METHODS. A total of 10 adults with recurrent GBM who had received first-line debulking surgery plus ...
Disclosure: IPAX-1 was sponsored by Telix Pharmaceuticals. IPAX Linz is an investigator-initiated trial; IMP was provided by Telix Pharmaceuticals.Pichler JLeibetseder AHllmüller IFeichtinger JDierneder JOsipova OPichler RNeuro-Oncology
The objective of IPAX-2 (NCT05450744) is to evaluate the safety and tolerability of [131I]IPA in patients newly diagnosed with GBM. METHODS. IPAX-2 is a phase 1, multicenter, open-label, single-arm, parallel-group, dose-finding study to evaluate the safety of ascending radioactive dose...